In addition, tigecycline preferentially sensitizes cells with increased mitochondrial translation, such as K-Ras mutant CRC cells and leukemia stem and progenitor cells, compared with their normal counterparts [39, 40]. This evidence concerns the gene KRAS and leukemia.